Table 3.
AIE cases by type.
| Type | Number | % of AIE |
|---|---|---|
| Seronegative | 22 | 27.8% |
| Anti‐LGI1 | 17 | 21.5% |
| Anti‐NMDA | 8 | 10.1% |
| ADEM | 7 | 8.9% |
| Undefined antibody on Immunofluorescence assay | 5 | 6.3% |
| Hashimoto | 5 | 6.3% |
| Anti‐GAD65 | 4 | 5.1% |
| Anti‐CASPR2 | 2 | 2.5% |
| Bickerstaff encephalitis | 2 | 2.5% |
| Anti‐Ma‐2 | 2 | 2.5% |
| ANNA2/Ri | 1 | 1.3% |
| Anti‐GFAP | 1 | 1.3% |
| Anti‐GABA‐B | 1 | 1.3% |
| PCA‐2/MAP1B | 1 | 1.3% |
| ANNA1/Hu | 1 | 1.3% |
| Total | 79 |
ANNA, anti‐neuronal nuclear antibody; ADEM, acute disseminated encephalomyelitis; CASPR2, contactin‐associated protein‐like 2; GABABR, gamma‐aminobutyric acid B receptors; GAD65, glutamic acid decarboxylase 65‐kilodalton isoform; GFAP, Glial fibrillary acidic protein; LGI1, leucine‐rich glioma inactivated 1; MAP1B, microtubule associated protein 1B; NMDAR, N‐methyl‐D‐aspartate receptor; PCA, Purkinje cell antibody.